Protalix Revenue Jumps 16 Percent in Q2

Protalix BioTherapeutics (NYSEMKT:PLX), a biopharmaceutical company specializing in plant cell-based protein production, announced its second quarter results on August 14, 2025. Revenues from product sales grew 16% to $15.4 million compared to Q2 2024. GAAP revenue of $15.6 million was slightly ahead of the $15.53 million analyst estimate. Despite this top-line beat, the company reported GAAP earnings per share (EPS) of $0.00, missing analyst expectations of $0.04 GAAP EPS. The result was influenced by a significant increase in research and development costs as the company prepared for a key clinical trial. Overall, the quarter showed strong commercial traction for Elfabrio®, gains in gross profit, and a return to quarterly profitability (GAAP). Source: Analyst estimates for the quarter provided by FactSet. Protalix BioTherapeutics develops and markets enzyme replacement therapies using its proprietary ProCellEx technology, a plant cell-based system for manufacturing complex proteins. This technology supports its two commercial enzyme replacement therapy (ERT) products: Elfabrio, for Fabry disease, and Elelyso, for Gaucher disease. Both address rare genetic disorders by replacing missing enzymes in patients. The company is also advancing new drug candidates, with its most developed pipeline asset being PRX-115 for uncontrolled gout.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool